Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Emery

Showing results (51-60 of 732) with videos related to

Pageof 74
Sort By:
Best Practice & Research. Clinical Rheumatology|December 14, 2004
Are early arthritis clinics necessary?Mark A Quinn, Paul Emery
Best Practice & Research. Clinical Rheumatology|December 10, 2013
Is there a place for initial treatment with biological DMARDs in the early phase of RA?Jackie L Nam, Paul Emery
Drugs of Today (Barcelona, Spain : 1998)|March 17, 2006
AbataceptEdward M Vital, Paul Emery
Rheumatology (Oxford, England)|January 10, 2014
Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targetsDaniel E Furst, Paul Emery
Panminerva Medica|December 2, 2024
Rheumatoid arthritis: a review of the key clinical features and ongoing challenges of the diseaseAndrea DI Matteo, Paul Emery
Current Opinion in Rheumatology|April 20, 2005
How should we manage early rheumatoid arthritis? From imaging to interventionHelen I Keen, Paul Emery
Journal of Autoimmunity|May 27, 2008
The development of targeted therapies in rheumatoid arthritisEdward M Vital, Paul Emery
British Journal of Hospital Medicine (London, England : 2005)|January 14, 2012
Biological therapy for rheumatoid arthritis: where are we now?Sarah C Horton, Paul Emery
Annals of the Rheumatic Diseases|February 19, 2016
Response to: 'Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required' by Moots et alPaul Emery, Jiří Vencovský, Jeehoon Ghil
Oxford Medical Case Reports|August 13, 2016
Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapyKavitha Nadesalingam, Mark Goodfield, Paul Emery
Pageof 74

Showing results (51-60 of 732) with videos related to

Sort By:
Pageof 74
Best Practice & Research. Clinical Rheumatology|December 14, 2004
Are early arthritis clinics necessary?Mark A Quinn, Paul Emery
Best Practice & Research. Clinical Rheumatology|December 10, 2013
Is there a place for initial treatment with biological DMARDs in the early phase of RA?Jackie L Nam, Paul Emery
Drugs of Today (Barcelona, Spain : 1998)|March 17, 2006
AbataceptEdward M Vital, Paul Emery
Rheumatology (Oxford, England)|January 10, 2014
Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targetsDaniel E Furst, Paul Emery
Panminerva Medica|December 2, 2024
Rheumatoid arthritis: a review of the key clinical features and ongoing challenges of the diseaseAndrea DI Matteo, Paul Emery
Current Opinion in Rheumatology|April 20, 2005
How should we manage early rheumatoid arthritis? From imaging to interventionHelen I Keen, Paul Emery
Journal of Autoimmunity|May 27, 2008
The development of targeted therapies in rheumatoid arthritisEdward M Vital, Paul Emery
British Journal of Hospital Medicine (London, England : 2005)|January 14, 2012
Biological therapy for rheumatoid arthritis: where are we now?Sarah C Horton, Paul Emery
Annals of the Rheumatic Diseases|February 19, 2016
Response to: 'Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required' by Moots et alPaul Emery, Jiří Vencovský, Jeehoon Ghil
Oxford Medical Case Reports|August 13, 2016
Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapyKavitha Nadesalingam, Mark Goodfield, Paul Emery
Pageof 74